Detail of the clinical trial
| Title of the trial | A phase 3, multi-center, randomised, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of lenalidomide (Revlimid) as maintenance therapy for patients with b-cell chronic lymphocytic leukemia following second-line therapy (the continuum trial) |
|---|---|
| EudraCT number | 2007-001626-27 |
| Protocol number | CC-5013-CLL-002 |
| Sponsor | Celgene Corporation, USA |
| Indications | Hemato-oncology |
| Diagnosis | B-cell chronic lymphocytic leukemia |
| Population in clinical trial |
Adults (18-65 years) Elderly ( > 65 years) Male Female Patients |
| Year of receiving the request to Institute (SÚKL) | 2008 |
| Date of approval by Institute (SÚKL) | 11.03.2009 |
| Date of approval by EC | 10.06.2009 |
| Date of initiation CT in ČR | 27.10.2009 |
| Date of ending CT in ČR | |
| Notice | |
| Sites |
FN KV, Šrobárova, Praha 10 (discontinued) Hematologie, Komplexní onkologické centrum Nový Jičín, Máchova Hematoonkologické oddělení, FN Plzeň Interní hematoonkologická klinika, FN Brno 1. interní klinika - klinika hematologie, 1. LF a VFN v Praze (discontinued) 2. interní klinika, odd. klinické hematologie, FN Hradec Králové (discontinued) |
cz